Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

BACKGROUND: Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The FUJI cohort aimed to confirm the real-life overall and progression-free survival (OS, PFS) and safety of cabazitaxel. METHODS: Multicentre, non-interventional cohort of Fren...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Rouyer, Magali, Oudard, Stéphane, Joly, Florence, Fizazi, Karim, Tubach, Florence, Jove, Jérémy, Lacueille, Clémentine, Lamarque, Stéphanie, Guiard, Estelle, Balestra, Aurélie, Droz-Perroteau, Cécile, Fourrier-Reglat, Annie, Moore, Nicholas
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6964680/
https://ncbi.nlm.nih.gov/pubmed/31719685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0611-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados